Foemosa Eyeware

Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company based in Taiwan, primarily focused on the development of high-value therapeutics in ophthalmology and oncology. The company's lead asset, APP13007 (clobetasol propionate ophthalmic suspension), received US FDA approval in 2024 for the treatment of inflammation and pain following ocular surgery. Formosa leverages its proprietary Activ-Pulverization Nanotechnology (APNT) platform to enhance the bioavailability and delivery of poorly soluble active pharmaceutical ingredients. Beyond its ophthalmic portfolio, the company is advancing a pipeline of antibody-drug conjugates (ADCs) and biosimilars, including TSY-110, a biosimilar of Kadcyla for breast cancer. Formosa Pharmaceuticals operates through a strategy of regional licensing and global partnerships to commercialize its innovative formulations.